2026-06-03T08:18:42Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/289532026-02-03T11:31:23Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Martinez, Esteban author Negredo, Eugenia author Knobel, Hernando author Ocampo, Antonio author Sanz, José author Garcia-Fraile, Lucio author Martin-Carbonero, Luz author Lozano, Fernando author González-Doménech, Carmen María author Gutierrez, Mar author Montero, Marta author Boix, Vicente author Payeras, Antoni author Torralba, Miguel author González-Cordón, Ana author Alejos, Belén author Pérez-Elías, María Jesús author 2019-10-05 Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens. Methods: A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. Results: There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA <50 copies/mL and 88% had ≥200 CD4 cells/mm3) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged <50 years, with prior AIDS and darunavir plus ritonavir use, and with CD4 cells <200/mm3 and with detectable viral load at initiation of darunavir/cobicistat; dual therapy was more common with previous intravenous drug use, detectable viral load at initiation of darunavir/cobicistat and no prior darunavir plus ritonavir; and four-drug therapy was more common with prior AIDS and detectable viral load at initiation of darunavir/cobicistat. Monotherapy and dual therapy showed a trend to better virological responses than triple therapy. CD4 responses and adverse effects did not differ among regimens. Discussion: Darunavir/cobicistat use in Spain has been tailored according to clinical characteristics of HIV-infected patients. Monotherapy and dual therapy have been common and preferentially addressed to older patients with a better HIV status, suggesting that health issues other than HIV infection may have been strong determinants of its prescription. Martinez E, Negredo E, Knobel H, Ocampo A, Sanz J, Garcia-Fraile L, Martin-Carbonero L, Lozano F, Gonzalez-Domenech CM, Gutierrez M, Montero M, Boix V, Payeras A, Torralba M, Gonzalez-Cordon A, Moreno A, Alejos B, Perez-Elias MJ; GeSIDA 9316 CODAR Study Group. Factors associated with the number of drugs in darunavir/cobicistat regimens. J Antimicrob Chemother. 2020 Jan 1;75(1):208-214. doi: 10.1093/jac/dkz399. https://hdl.handle.net/10630/28953 10.1093/jac/dkz399 SIDA - Tratamiento Infecciones por VIH - Tratamiento Mononucleosis - Tratamiento Agentes antivíricos Factors associated with the number of drugs in darunavir/cobicistat regimens.